Indoco Remedies' Q4 FY 2025-26 Quarterly Results

Result Summary

• Indoco Remedies Ltd reported a 6.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 21.2%.
• Its expenses for the quarter were up by 7.0% QoQ and 15.2% YoY.
• The net profit decreased 19.6% QoQ and decreased 42.7% YoY.
• The earnings per share (EPS) of Indoco Remedies Ltd declined at 2.56 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Indoco Remedies Ltd is a prominent player in the pharmaceutical industry, known for its diverse range of pharmaceutical formulations. The company caters to both domestic and international markets, offering a variety of products that include prescription drugs, over-the-counter medications, and active pharmaceutical ingredients (APIs). Indoco Remedies focuses on areas such as ophthalmology, respiratory, and anti-infectives, amongst others. It is engaged in both the manufacturing and distribution of its products. Any recent developments within the company are not specified within the provided data, but the pharmaceutical sector generally faces dynamic changes due to regulatory shifts, market demand, and innovation.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Indoco Remedies Ltd reported a total income of ₹475.57 crores. This represents a quarter-over-quarter (QoQ) increase of 6.5% from the previous quarter (Q3FY26), where total income was ₹446.34 crores. Furthermore, on a year-over-year (YoY) basis, comparing Q4FY26 to Q4FY25, the total income rose by 21.2%, from ₹392.23 crores. These figures suggest an upward trend in revenue generation for the company over the specified periods.

Profitability

Indoco Remedies Ltd reported a Profit Before Tax (PBT) of ₹-25.00 crores for Q4FY26, reflecting an improvement of 20.2% QoQ from Q3FY26, where the PBT was ₹-31.31 crores. Compared to the same quarter in the previous fiscal year (Q4FY25), the PBT improved by 45.1% from ₹-45.52 crores. The company's Profit After Tax (PAT) for Q4FY26 was ₹-23.68 crores, a QoQ improvement of 19.6% from Q3FY26's PAT of ₹-29.45 crores, and a 42.7% YoY improvement from ₹-41.34 crores in Q4FY25. This progression in profitability metrics is also reflected in the Earnings Per Share (EPS), which improved from ₹-4.48 in Q4FY25 to ₹-2.56 in Q4FY26, marking a 42.9% YoY enhancement.

Operating Metrics

The total expenses for Indoco Remedies Ltd in Q4FY26 were ₹504.31 crores, showing a QoQ increase of 7.0% from ₹471.50 crores in Q3FY26. On a YoY basis, total expenses rose by 15.2% from ₹437.75 crores in Q4FY25. The tax expense for Q4FY26 was ₹-1.32 crores, which displayed a reduction of 29.0% QoQ from Q3FY26 and a significant 68.4% decrease YoY compared to Q4FY25. These operational metrics highlight the company's financial dynamics in terms of managing income and expenses across different periods.